Shots:

• The US FDA’s approval is based on four clinical studies (ACHIEVE I- ACHIEVE II- UBR-MD-04 and 3110-105-002)- which demonstrated efficacy- safety and tolerability of Ubrelvy (50- 100mg) for the acute treatment of migraine with/-out aura in adults
• The studies resulted in meeting its 1EPs i.e- elimination in migraine pain and the most bothersome symptom (nausea- hypersensitivity to light and sound)- providing lasting relief up to 24 hrs.
• Ubrelvy is the first orally administered CGRP receptor antagonist (gepant)- act without constricting blood vessels with no potential to cause addiction. The therapy is expected to be available in Q1’20

Click here to­ read full press release/ article | Ref: Allergan | Image: Nove.firenze